Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 25 May

Grady Wulff
May 25, 2023

Morning Bell 24 May

Grady Wulff
May 24, 2023

Morning Bell 23 May

Grady Wulff
May 23, 2023

Weekly Wrap 12 May

Grady Wulff
May 12, 2023

Morning Bell 12 May

Sophia Mavridis
May 12, 2023

Morning Bell 11 May

Grady Wulff
May 11, 2023

Morning Bell 10 May

Grady Wulff
May 10, 2023

Morning Bell 9 May

Sophia Mavridis
May 9, 2023

Morning Bell 8 May

Grady Wulff
May 8, 2023

Weekly Wrap 5 May

Sophia Mavridis
May 5, 2023

Morning Bell 4 May

Grady Wulff
May 4, 2023